An Open-Label Pharmacokinetic Study in De Novo Renal Transplant Subjects Receiving a Belatacept Based Immunosuppressant Regimen.
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2014
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 28 Feb 2012 Planned end date changed from 1 Aug 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 20 Oct 2008 Basic check conducted, last updated 26-09-2008.